Pfizer Target of Unusually Large Options Trading (NYSE:PFE)
Pfizer, Inc. (NYSE:PFE) was the recipient of some unusual options trading on Tuesday. Traders purchased 21,983 put options on the stock. This represents an increase of approximately 351% compared to the average volume of 4,871 put options.
Several equities research analysts recently issued reports on the company. Credit Suisse Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $38.00 to $36.00 in a report on Thursday. Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the company a “buy” rating in a report on Monday. Jefferies Group LLC reiterated a “hold” rating and issued a $35.00 price objective (up previously from $34.00) on shares of Pfizer in a report on Friday, July 14th. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating in a report on Friday, July 14th. Finally, BidaskClub downgraded Pfizer from a “sell” rating to a “strong sell” rating in a report on Thursday, July 13th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and ten have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $37.68.
Hedge funds have recently made changes to their positions in the company. Orbimed Advisors LLC raised its stake in shares of Pfizer by 46.3% in the fourth quarter. Orbimed Advisors LLC now owns 5,167,900 shares of the biopharmaceutical company’s stock worth $167,853,000 after buying an additional 1,635,700 shares during the last quarter. Paulson & CO. Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth about $11,439,000. E&G Advisors LP raised its stake in shares of Pfizer by 6.8% in the first quarter. E&G Advisors LP now owns 62,258 shares of the biopharmaceutical company’s stock worth $2,130,000 after buying an additional 3,940 shares during the last quarter. Prentiss Smith & Co. Inc. raised its stake in shares of Pfizer by 1.7% in the first quarter. Prentiss Smith & Co. Inc. now owns 14,948 shares of the biopharmaceutical company’s stock worth $511,000 after buying an additional 250 shares during the last quarter. Finally, Carroll Financial Associates Inc. raised its stake in shares of Pfizer by 33.9% in the first quarter. Carroll Financial Associates Inc. now owns 197,820 shares of the biopharmaceutical company’s stock worth $6,767,000 after buying an additional 50,045 shares during the last quarter. 69.95% of the stock is currently owned by institutional investors and hedge funds.
Pfizer (PFE) opened at 33.54 on Friday. Pfizer has a 12-month low of $29.83 and a 12-month high of $37.39. The stock has a 50 day moving average price of $33.20 and a 200-day moving average price of $33.25. The stock has a market cap of $200.16 billion, a P/E ratio of 28.23 and a beta of 1.01.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.02. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. The business had revenue of $12.78 billion for the quarter, compared to analyst estimates of $13.09 billion. During the same period in the previous year, the company earned $0.67 earnings per share. The company’s revenue for the quarter was down 1.7% compared to the same quarter last year. On average, equities analysts expect that Pfizer will post $2.55 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.82%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s payout ratio is 108.48%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.